NETCOMM-WIRELESS-LIMITED
24.2.2015 09:01:07 CET | Business Wire | Pressemeddelelse
NetComm Wireless Limited (ASX:NTC) , is pleased to introduce the OMA Lightweight M2M (LWM2M) Enabler which addresses a significantly larger global Machine-to-Machine (M2M) market by standardising processes for simple and economical remote management between M2M devices and their management platforms. NetComm Wireless' LWM2M client implementation is now ready for field trials following successful interoperability testing with a number of LWM2M servers from different vendors at the recent OMA LWM2M test fest in Dusseldorf, Germany.
The OMA Lightweight M2M (LWM2M) Enabler will bolster large-scale M2M market growth by facilitating lower development and operational costs, greater flexibility, less fragmentation and faster time-to-market through the introduction of a new remote device management protocol that enables greater interoperability between M2M devices and M2M remote management servers and platforms. The new standard is suitable for the whole M2M and Internet of Things (IoT) market, providing support for remote device management and simple M2M application management using the same solution.
Designed to meet the remote management needs of resource constrained devices such as temperature or fluid level sensors that need to run at a low cost, LWM2M will be of particular benefit in areas where M2M solutions must be deployed at minimal cost to ensure sustainable business models and viable mass deployments.
"LWM2M is essential for overcoming the obstacles of an inflexible M2M landscape and will bring about a much needed move away from today's fragmented and proprietary solutions. Interoperability testing in Dusseldorf has shown NetComm Wireless to have the most advanced implementation on the device side and we are pleased to be among the first to introduce M2M devices that work with any LWM2M management platform to unleash the full potential of wireless M2M and IoT," said David Stewart, CEO and Managing Director, NetComm Wireless.
The OMA Lightweight M2M (LWM2M) Enabler transfers a minimal amount of data between devices and their management platforms, using any network, to improve the practicality and reduce the operational cost of M2M in areas such as smart cities, smart homes, smart metering, tracking, industry and agriculture. The new device management protocol overcomes the constraints of high development costs, proprietary limitations and scalability by offering standardised device management as well as a small central processing unit and memory footprint and simplified M2M application development.
Although the use cases differ, remote communication, configuration and control capabilities are a central requirement for any M2M deployment. The new protocol significantly drives down the cost and complexity of carrying out critical device management tasks such as: bootstrapping and registration, firmware updates, remote configuration, parameter retrieval, event notifications, remote diagnostics and remote reboot.
Lightweight M2M key benefits:
- Modern architectural design will appeal to software developers
- A data model that is extensible to enable any kind of M2M service
- Designed with the resource constraints of M2M devices in mind to enable low-cost devices
- Builds on an Internet-style protocol called CoAP (Constrained Application Protocol) which is highly optimized for M2M services
- Efficient state-of-the-art security based on DTLS
- Can be used across any type of network
NetComm Wireless will showcase its latest technologies at Mobile World Congress 2015, 2-5 March in Barcelona, Spain. Visit us at Hall 2, booth 2B19MR; and see a live demonstration at the OMA exhibit in the App Planet Hall 8.1, stand K52.
About NetComm Wireless Limited
NetComm Wireless Limited (ASX: NTC) is a leading developer of Machine-to-Machine (M2M) devices and solutions globally. The company provides 3G, 4G and rural broadband new generation fixed-wireless devices that underpin an increasingly connected world. Leading telecommunications carriers, core network providers and system integrators utilise NetComm Wireless' solutions to optimise network performance and to support their connected products and services in the M2M and rural broadband markets. For the past 32 years, NetComm Wireless has developed a portfolio of world first data communication products, and is now a globally recognised wireless innovator. Headquartered in Sydney (Australia), NetComm Wireless has offices in the US, Europe/UK, New Zealand, Middle East and Japan. For more information visit www.netcommwireless.com .
Contact:
NetComm Wireless
Yumi Bondy, +61 449 903 087
yumi.bondy@netcommwireless.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum